Phase III, double-blind, placebo-controlled, randomized, multicenter, international trial with Durvalumab plus Oleclumab and Durvalumab plus Monalizumab in patients with locally advanced (stage III) and unresectable non-small cell lung cancer (NSCLC) who have not progressed after a definitive concomitant platinum-based chemoradiotherapy (PACIFIC-9).
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ASTRAZENECA FARMACEUTICA ESPAÑA SA
- Phase: III
- Execution start: 14/03/2022
- End of execution: 30/10/2030
- IP: SILVIA SEQUERO LOPEZ